ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2023
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed.
- Physician referral is associated with recruitment, motivation, and adherence in an exercise intervention study for older adults.Journal of the National Medical Association · 2026Trial
- Feasibility and effects of cognitive training on cognition and psychosocial function in Huntington's disease: a randomised pilot trial.Journal of neurology · 2025Trial
- Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer's Disease Randomized Controlled Trial.The journal of prevention of Alzheimer's disease · 2024Trial
- Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program.The journal of prevention of Alzheimer's disease · 2023Trial
- Autopsy findings in Alzheimer's disease clinical trial participants demonstrate a high frequency of off-target coexisting pathologic features.The journal of prevention of Alzheimer's disease · 2026Article
- Article
- Interpretable 2D Deep Learning for Alzheimer's Detection from sMRI: A Lightweight Residual CNN Approach with Comprehensive Preprocessing and Stratified Data Partitioning.Sensors (Basel, Switzerland) · 2026Article
- Evaluating evidence-based recruitment strategies for Alzheimer's disease and related dementias clinical trial research: A literature review.The journal of prevention of Alzheimer's disease · 2026Review
- Differences in amyloid PET positivity based on ethnoracial group and social determinants of health: The new IDEAS study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Minor neuropsychological deficits and stage 2 of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Translating evidence into practice: adapting TrialGPT for real-world clinical trial eligibility screening.Journal of the American Medical Informatics Association : JAMIA · 2026Article
- Outreach, Recruitment and Engagement Cores of NIA-designated Alzheimer's Disease Research Centers: Current strategies and future directions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Domain-adapted language model using reinforcement learning for various dementias.medRxiv : the preprint server for health sciences · 2026Article
- Cognitive screening biases in a secondary prevention Alzheimer's disease clinical trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The Utility of Speech and Language Analytics for Screening Alzheimer's Disease.Neuro-degenerative diseases · 2026Review
- Successful strategies for supporting diverse representation in Alzheimer's disease research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Scalable biological-cognitive profiling for Alzheimer's disease in the population.Brain communications · 2026Article
- From engagement to dissemination: a WiseAge patient and public involvement and engagement event on dementia with Lewy bodies.Frontiers in dementia · 2026Article
- AI-augmented frameworks for enhancing Alzheimer's disease clinical trials: A memory clinic perspective.The journal of prevention of Alzheimer's disease · 2025Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Clinical trials for Alzheimer's disease (AD) are slower to enroll study participants, take longer to complete, and are more expensive than trials in most other therapeutic areas. The recruitment and retention of a large number of qualified, diverse volunteers to participate in clinical research studies remain among the key barriers to the successful completion of AD clinical trials. An advisory panel of experts from academia, patient-advocacy organizations, philanthropy, non-profit, government, and industry convened in 2020 to assess the critical challenges facing recruitment in Alzheimer's clinical trials and develop a set of recommendations to overcome them. This paper briefly reviews existing challenges in AD clinical research and discusses the feasibility and implications of the panel's recommendations for actionable and inclusive solutions to accelerate the development of novel therapies for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.